Dr Colin Petrie
- Honorary Clinical Senior Lecturer (School of Cardiovascular & Metabolic Health)
Publications
2026
Taylor Sweet, D. et al. (2026) Targeted assessment in high-risk patients with diabetes to identify undiagnosed heart failure (TARTAN-HF). Journal of the American College of Cardiology, (Accepted for Publication)
2024
Lee, M. et al. (2024) Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic – insights from the IRONMAN trial. European Journal of Heart Failure, 26(10), pp. 2293-2295. (doi: 10.1002/ejhf.3394) (PMID:39078467)
Lee, M. et al. (2024) Heart Failure – Chronic Heart Failure, Pathophysiology and Mechanisms, Heart Failure with Reduced Ejection Fraction (HFrEF). Ferric Derisomaltose in Hospitalised and Ambulatory Patients with Heart Failure-Insights from the IRONMAN trial. Heart Failure 2024, Lisbon, Portugal, 11-14 May 2024. (doi: 10.1002/ejhf.3326)
Lee, M. et al. (2024) Efficacy of Intravenous Ferric Derisomaltose in Hospitalised and Outpatient Settings: Insights from Ironman Trial. British Cardiovascular Society Annual Conference 2024, Manchester, UK, 3–5 June 2024. (doi: 10.1136/heartjnl-2024-BCS.135)
Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, 45(16), pp. 1410-1426. (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (PMCID:PMC11032711)
2022
Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)
2021
Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)
2020
Maznyczka, A. M. et al. (2020) Comparative significance of invasive measures of microvascular injury in acute myocardial infarction. Circulation: Cardiovascular Interventions, 13(5), e008505. (doi: 10.1161/CIRCINTERVENTIONS.119.008505) (PMID:32408817) (PMCID:PMC7237023)
Maznyczka, A. M. et al. (2020) One-year outcomes after low-dose intracoronary alteplase during primary percutaneous coronary intervention. The T-TIME randomized trial. Circulation: Cardiovascular Interventions, 13(2), e008855. (doi: 10.1161/CIRCINTERVENTIONS.119.008855) (PMID:32069113)
Articles
Taylor Sweet, D. et al. (2026) Targeted assessment in high-risk patients with diabetes to identify undiagnosed heart failure (TARTAN-HF). Journal of the American College of Cardiology, (Accepted for Publication)
Lee, M. et al. (2024) Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic – insights from the IRONMAN trial. European Journal of Heart Failure, 26(10), pp. 2293-2295. (doi: 10.1002/ejhf.3394) (PMID:39078467)
Cleland, J. G.F. et al. (2024) Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. European Heart Journal, 45(16), pp. 1410-1426. (doi: 10.1093/eurheartj/ehae086) (PMID:38446126) (PMCID:PMC11032711)
Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)
Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)
Maznyczka, A. M. et al. (2020) Comparative significance of invasive measures of microvascular injury in acute myocardial infarction. Circulation: Cardiovascular Interventions, 13(5), e008505. (doi: 10.1161/CIRCINTERVENTIONS.119.008505) (PMID:32408817) (PMCID:PMC7237023)
Maznyczka, A. M. et al. (2020) One-year outcomes after low-dose intracoronary alteplase during primary percutaneous coronary intervention. The T-TIME randomized trial. Circulation: Cardiovascular Interventions, 13(2), e008855. (doi: 10.1161/CIRCINTERVENTIONS.119.008855) (PMID:32069113)
Conference or Workshop Item
Lee, M. et al. (2024) Heart Failure – Chronic Heart Failure, Pathophysiology and Mechanisms, Heart Failure with Reduced Ejection Fraction (HFrEF). Ferric Derisomaltose in Hospitalised and Ambulatory Patients with Heart Failure-Insights from the IRONMAN trial. Heart Failure 2024, Lisbon, Portugal, 11-14 May 2024. (doi: 10.1002/ejhf.3326)
Lee, M. et al. (2024) Efficacy of Intravenous Ferric Derisomaltose in Hospitalised and Outpatient Settings: Insights from Ironman Trial. British Cardiovascular Society Annual Conference 2024, Manchester, UK, 3–5 June 2024. (doi: 10.1136/heartjnl-2024-BCS.135)